

Current report No. 24/2019

Date prepared: 2019-08-14

Abbreviated name of the issuer: MABION S.A.

Subject: Information on cooperation with Mylan.

Legal basis: Article 17, paragraph 1 MAR – confidential information

Content of the report:

With reference to the information about the intention to merge Mylan NV (Mylan) with Upjohn - an entity separated from the Pfizer group and the statement of the Company's Management Board posted on the Mabion S.A.'s (Mabion, the Company) website in this matter; in the context of the Mabion and Mylan teams' cooperation within the scope of the registration of MabionCD20 drug on the European market, the Management Board of Mabion informs that in response to its inquiry, it received today an information from the Mylan legal department that at the moment they do not anticipate the impact of the planned merger on the binding agreement between parties (Development and Commercialization Agreement), signing of which - the Company announced in current report no. 31/2016 of November 8, 2016.

In the event of significant changes in this area, the Company will inform about it the market in a current report.